Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2025)

Crinetics Pharmaceuticals (CRNX) has 5 years of Current Leases data on record, last reported at $6.5 million in Q4 2025.

  • For Q4 2025, Current Leases fell 9.27% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, down 9.27%, while the annual FY2025 figure was $6.5 million, 9.27% down from the prior year.
  • Current Leases reached $6.5 million in Q4 2025 per CRNX's latest filing, up from $6.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $7.4 million in Q2 2024 and bottomed at $939000.0 in Q4 2021.
  • Average Current Leases over 5 years is $4.5 million, with a median of $5.8 million recorded in 2024.
  • Peak YoY movement for Current Leases: surged 571.33% in 2024, then decreased 13.11% in 2025.
  • A 5-year view of Current Leases shows it stood at $939000.0 in 2021, then grew by 11.93% to $1.1 million in 2022, then surged by 297.05% to $4.2 million in 2023, then skyrocketed by 71.39% to $7.2 million in 2024, then fell by 9.27% to $6.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $6.5 million in Q4 2025, $6.4 million in Q3 2025, and $6.6 million in Q2 2025.